Fate Therapeutics
FATE
21 hedge funds and large institutions have $92.8M invested in Fate Therapeutics in 2014 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 3 closing their positions.
276% more capital invested
Capital invested by funds: $24.7M → $92.8M (+$68.2M)
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
31% more funds holding
Funds holding: 16 → 21 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.6M |
| 2 |
KCM
Kingdon Capital Management
New York
|
+$1.94M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1M |
| 4 |
Bank of New York Mellon
New York
|
+$297K |
| 5 |
U
UBS
Zurich,
Switzerland
|
+$185K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$2.08M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$587K |
| 3 |
Millennium Management
New York
|
-$165K |
| 4 |
Goldman Sachs
New York
|
-$113K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$76K |
FATE Hedge Fund Activity: Q1 2014 in Review
21 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q1 2014, worth a combined $92.8M — up 276% from $24.7M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new FATE positions and 3 closed out — a net gain of 5 holders — while 4 added to existing stakes and 6 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $23.6M. The largest seller was Farallon Capital Management, cutting an estimated $2.08M.
- 21 institutional investors held Fate Therapeutics (FATE) as of Q1 2014, up from 16 in Q4 2013.
- Funds reported $92.8M of Fate Therapeutics stock for Q1 2014, up 276% quarter-over-quarter.
- 8 funds opened new Fate Therapeutics positions in Q1 2014 and 3 closed out, a net change of +5 holders.
- The largest Fate Therapeutics buyer in Q1 2014 was Fidelity Investments, an estimated $23.6M added.
- The largest Fate Therapeutics seller in Q1 2014 was Farallon Capital Management, an estimated $2.08M sold.
Based on aggregated 13F filings for Q1 2014.